Tag: mark ibberson group

Can technologies like ChatGPT support life science researchers in exploring data they are not familiar with? This is the question our new Knowledge Representation unit investigated, through concrete examples from SIB’s leading open databases and...

SIB takes part in the international project ENDOTARGET launched this month.

Discover the SwissBioData ecosystem, a proposal by the SIB Swiss Institute of Bioinformatics and 13 Swiss institutions, which aims at enabling next-generation data-driven research to boost Switzerland’s capacity to convert biological and biomedical...

European research organisations, pharmaceutical companies, SME’s and patient organisations have joined forces as partners to develop innovative personalised treatment options for people affected by psoriatic arthritis. SIB is delivering core data...

Thanks to a unique dataset from living donors, and innovative multi-omics analysis, an international research team led by investigators at the Paul-Langerhans-Institute Dresden (PLID), the SIB Swiss Institute of Bioinformatics and the...

Capturing biological pathways is a massive database challenge: it implies representing metabolites in a way that is understandable to both humans and computers, and which enables their interconnection through the biochemical reactions they engage...

Addex Therapeutics and SIB have been awarded a CHF600K Innosuisse grant to apply computational approaches developed by SIB to identify new therapeutic indications for a potent and selective dopamine D1 receptor antagonist.

In its latest version, the cancer diagnostics platform developed jointly by the Geneva University Hospitals (HUG) and SIB offers key additional molecular insights.

Focus on the group's mission The Vital-IT team provides bioinformatics collaborative support to life science projects in Switzerland and abroad through collaborations with academic and industry partners. Thanks to its diverse expertise in...

Data management We organize, clean & control the quality of your datasets for subsequent analysis. In addition, we can process, transform and align your datasets to existing standards and make them available as a database. We can propose...

SIB is joining the consortium ‘SOPHIA’ (Stratification of Obese Phenotypes to Optimize Future Obesity Therapy), which aims to improve risk assessment of complications of obesity and predict treatment response for people with obesity.

Are you working with multi-omics and aiming to make the generated data shareable and reusable? Find out what it entails and some of the tools that may help.

A new Internal Group, Core-IT, is now bringing SIB’s existing IT-related expertise under one roof, with a specific focus on data protection, quality assurance and information security. Together with the recognized excellence of Vital-IT in...

Today, we present an overview of the BioMedIT project, coordinated by SIB’s Personalized Health Informatics Group, as the first of a series of articles on SIB’s role in the development of a personalized health research infrastructure in...

SIB is lending its expertise in data management to the FAIRplus project, aiming to increase the discovery, accessibility and reusability of data from selected projects funded by the European Innovative Medicines Initiative (IMI), as well as...

Fifteen years after its creation, Vital-IT – one of SIB’s largest groups and Switzerland’s earliest bioinformatics core facility – continues to evolve. Find out how the Group is consolidating its position as the reference in bioinformatics for...

Every minute, each one of our trillions of cells carries out countless chemical reactions to convert food into energy, build proteins and eliminate toxic waste for instance. Taken as a whole, all these reactions make up our metabolism. But by which...

A national network to support the data science needs of life scientists Find below the core facilities and competence centres at SIB and in the major Swiss academic institutions that are managed by SIB Group Leaders. Discover the SwissBioData...

Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society - among which SIB's Vital-IT Group and the University of Lausanne - have joined forces to fight diabetes.

A study led by a team of researchers from the Institute of Microbiology of CHUV-UNIL and SIB Swiss Institute of Bioinformatics reveals the mechanisms of antigenic variation used by the pathogen Pneumocystis jirovecii to escape the human immune...

A study carried out by researchers at the University of Lausanne (UNIL) and the SIB Swiss Institute of Bioinformatics has revealed that the genome of an emblematic tree of the University campus, the Napoleon oak, has changed little during its first...

Type 2 diabetes, which affects >0.5 billion people worldwide, results from the inability of pancreatic beta cells to provide the body with enough insulin to maintain healthy levels of blood glucose. As part of the IMIDIA initiative, an...

Update on the Swiss Personalized Health Network (SPHN) Designed to promote the development of personalized health in Switzerland, the SPHN initiative will lay the foundations to foster research projects in this area, including mechanisms...

As announced in May, Alan Bridge is taking up the co-director role of SIB’s Swiss-Prot Group, thus succeeding to Lydie Bougueleret. He gives us his vision of the future for a unique profession, biocuration, and for the Swiss-Prot Group, one of its...

A push for a paradigm change in scientific publication. Bringing to the surface information buried in the figures of scientific papers: this is the purpose of SourceData, an open-access platform developed by EMBO in collaboration with the SIB Swiss...

Entrepreneurs, Scientists, Journalists, Artists... Each year, the Forum des 100 lists and brings together 100 personalities who contribute to the dynamism and spirit of innovation of Western Switzerland.Prof. Ioannis Xenarios is among the laureates...

When it comes to fighting cancer, obtaining a diagnosis a day earlier, as well as saving one full day per week of clinical lab professionals’ precious time, can have important benefits for patients, hospitals and health insurance alike. This and...

Last September, we were announcing SIB’s participation in a European public-private partnership on Risk Assessment and Progression of Diabetes (RHAPSODY).Watch this short video to learn more about SIB’s role in the project.

“Stick out your tongue and say... ‘omics’”.In addition to patients’ vital signs or eating habits, molecular profiling data is increasingly becoming part of the medical practitioners’ toolbox. But these ‘omics’ data pose novel challenges, for...

Recent advances in the fight against type 2 diabetes (T2D) result from a pan-European collaborative project, called IMIDIA, in which the SIB Swiss Institute of Bioinformatics is closely involved since 2010.

Bringing medicinal chemistry and bioinformatics to the layman, by using a didactic online platform based on professional tools, is the goal of the Drug Design Workshop. Developed in 2015 by SIB researchers, together with training and outreach...